Master Protocols-including platform, umbrella, and basket trials-offer significant benefits and efficiencies in drug development compared with traditional trial protocols. However, their perpetual nature, adaptive designs, and evolving requirements make randomisation inherently more complex. As a result, implementing and maintaining robust randomisation for Master Protocols can be challenging for sponsors. Selecting the right IRT provider is therefore critical. This paper outlines five essential questions sponsors should ask when evaluating IRT providers for Master Protocols, with a focus on long-term trial success, regulatory readiness, and operational resilience.
Date:
More like thisRelated
Deploy your applications securely and at scale.
Protect your data—and your bottom line.Discover:
Point-and-click tools to help...
Maak elke interactie persoonlijk met Agentforce Marketing
Ontdek hoe je campagnes kunt omzetten in gesprekken. Laat...
See What Your Agents Are Doing with Agentforce Observability
Take full control of your AI agent workforce with...
Speed and security work together with Agentforce Vibes.
Turn IT backlogs into breakthroughs.Agentforce Vibes lets your developers...